Interestingly, two recent in vivo CRISPR-Cas9 genome editing studies have demonstrated that deletion of APP-related genes is able to increase the efficacy of ICI-based immunotherapy in melanoma and renal carcinoma (81, 82). This evidence concerns the gene APP and renal carcinoma.